title: Hepatitis C: An Eastern Perspective.
abstract: HCV in the East is a complex scenario with prevalence rates of 0.5% to as high as 4.7%, and variable distributions of genotypes, with a dominance of genotype 1b in East Asia, genotype 3 in South Asia and South East Asia, and genotype 6 in Indochina. Approvals for the new oral directing antiviral agents (DAAs), in the East have been very slow, but ultimately will be achieved by 2019, consequently, pegylated interferon and ribavirin are still widely used. Nonetheless the main issues are the problems of screening and linkage to management, and the considerable barriers to access HCV care.
authors.affiliation: Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, 1E, Kent Ridge Road, NUHS Tower Block Level 10, Singapore 119228, Singapore; Division of Gastroenterology and Hepatology, National University Health System, Singapore, Singapore; Cancer Science Institute, National University of Singapore, Singapore, Singapore.
authors.forename: Yock Young
authors.initials: YY
authors.lastname: Dan
authors.affiliation: Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, 1E, Kent Ridge Road, NUHS Tower Block Level 10, Singapore 119228, Singapore; Division of Gastroenterology and Hepatology, National University Health System, Singapore, Singapore; Cancer Science Institute, National University of Singapore, Singapore, Singapore; Institute of Molecular and Cell Biology, Agency for Science and Technology, 61 Biopolis Drive, Singapore 138673, Singapore; Department of Gastroenterology and Hepatology, National University Hospital, 1E Lower Kent Ridge Road, Singapore 119228, Singapore. Electronic address: mdclimsg@nus.edu.sg.
authors.forename: Seng Gee
authors.initials: SG
authors.lastname: Lim
mesh_terms: D000998:Antiviral Agents / Q000191:economics / Q000627:therapeutic use*; D001208:Asia / Q000453:epidemiology; D003362:Cost-Benefit Analysis; D005838:Genotype; D006291:Health Policy; D006297:Health Services Accessibility; D016174:Hepacivirus / Q000235:genetics*; D019698:Hepatitis C, Chronic / Q000188:drug therapy / Q000191:economics / Q000453:epidemiology / Q000821:virology; D006801:Humans
chemical_list: D000998:Antiviral Agents
keywords: Asia; Cost-effectiveness; Hepatitis C; Roadmap strategy